Genmab A/S
Carl Jacobsens Vej 30
Valby
Copenhagen 2500
Denmark
45 70 20 27 28
https://www.genmab.com
版塊: Healthcare
行業: Biotechnology
全職員工: 2,204
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, President & CEO | 2.86M | 無 | 1961 |
| Mr. Anthony Pagano | Executive VP & CFO | 1.02M | 無 | 1978 |
| Ms. Birgitte Stephensen M.Sc. | Executive VP & Chief Legal Officer | 629.18k | 無 | 1961 |
| Dr. Martine J. van Vugt Ph.D. | Executive VP & Chief Strategy Officer | 686.38k | 無 | 1971 |
| Mr. Martin Schultz | Senior Director of Clinical Operations & Non-Independent Director | 114.4k | 無 | 1976 |
| Dr. Tahamtan Ahmadi | Executive VP, Chief Medical Officer & Head of Experimental Medicines | 1.1M | 無 | 1973 |
| Dr. Mijke Zachariasse Ph.D. | Senior Director, Head of Antibody Research Materials & Non-Independent Director | 157.3k | 無 | 1974 |
| Mr. Takahiro Hamatani | Senior Director of Finance Japan & Non-Independent Director | 114.4k | 無 | 1975 |
| Mr. Anthony Mancini | Executive VP & COO | 1.09M | 無 | 1971 |
| Mr. Andrew Carlsen | Senior Director, VP & Head of Investor Relations | 無 | 無 | 無 |
描述
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
公司管治
截至 2024年4月29日 止，Genmab A/S 的 ISS 管治質素評分為 4。 Pillar 分數正在審核中：2；董事會：1；股東權利：1；現金賠償：8。
